{"protocolSection":{"identificationModule":{"nctId":"NCT04808934","orgStudyIdInfo":{"id":"X9001275"},"organization":{"fullName":"Pfizer","class":"INDUSTRY"},"briefTitle":"NOAC Portuguese Real World Study","officialTitle":"Stroke/Systemic Embolism and Major Bleeding in Patients Newly Treated With Oral Anticoagulants: a Real World Study From Portuguese Administrative Claims Data"},"statusModule":{"statusVerifiedDate":"2023-04","overallStatus":"WITHDRAWN","whyStopped":"Withdrawn due to COVID19 pandemic. Several delays affected this study, therefore company decided to not conduct the study. It was cancelled prior to any enrollment.","expandedAccessInfo":{"hasExpandedAccess":false},"startDateStruct":{"date":"2020-06-01","type":"ESTIMATED"},"primaryCompletionDateStruct":{"date":"2020-12-01","type":"ESTIMATED"},"completionDateStruct":{"date":"2020-12-01","type":"ESTIMATED"},"studyFirstSubmitDate":"2021-03-18","studyFirstSubmitQcDate":"2021-03-18","studyFirstPostDateStruct":{"date":"2021-03-22","type":"ACTUAL"},"lastUpdateSubmitDate":"2023-04-04","lastUpdatePostDateStruct":{"date":"2023-04-05","type":"ACTUAL"}},"sponsorCollaboratorsModule":{"responsibleParty":{"type":"SPONSOR"},"leadSponsor":{"name":"Pfizer","class":"INDUSTRY"}},"oversightModule":{"oversightHasDmc":false,"isFdaRegulatedDrug":true,"isFdaRegulatedDevice":false,"isUsExport":false},"descriptionModule":{"briefSummary":"To determine if there is any difference in the effectiveness and safety outcomes of patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban and vitamin K antagonists"},"conditionsModule":{"conditions":["Stroke","Systemic Embolism","Major Bleeding"]},"designModule":{"studyType":"OBSERVATIONAL","patientRegistry":false,"designInfo":{"observationalModel":"OTHER","timePerspective":"RETROSPECTIVE"},"bioSpec":{"retention":"NONE_RETAINED","description":"Not applicable, this is a retrospective study"},"enrollmentInfo":{"count":0,"type":"ACTUAL"}},"armsInterventionsModule":{"armGroups":[{"label":"Non-Valvular Atrial Fibrillation (NVAF) Adults","description":"Adult patients with NVAF newly treated with apixaban, dabigatran, rivaroxaban or VKAs between June 16, 2014 and December 31, 2018.","interventionNames":["Drug: Apixaban","Drug: dabigatran","Drug: rivaroxaban","Drug: VKAs"]}],"interventions":[{"type":"DRUG","name":"Apixaban","description":"Adults receiving apixaban","armGroupLabels":["Non-Valvular Atrial Fibrillation (NVAF) Adults"]},{"type":"DRUG","name":"dabigatran","description":"Adults receiving dabigatran","armGroupLabels":["Non-Valvular Atrial Fibrillation (NVAF) Adults"]},{"type":"DRUG","name":"rivaroxaban","description":"Adults receiving rivaroxaban","armGroupLabels":["Non-Valvular Atrial Fibrillation (NVAF) Adults"]},{"type":"DRUG","name":"VKAs","description":"Adults receiving VKA","armGroupLabels":["Non-Valvular Atrial Fibrillation (NVAF) Adults"]}]},"outcomesModule":{"primaryOutcomes":[{"measure":"stroke/systemic embolism event","description":"To compare the risk of stroke (either ischemic or hemorrhagic) or SE among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.","timeFrame":"between 2014 and 2018"},{"measure":"major bleeding event","description":"To compare the risk of major bleeding (gastrointestinal \\[GI\\], intracranial \\[IC\\] and other) among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versusVKAs.","timeFrame":"between 2014 and 2018"}],"secondaryOutcomes":[{"measure":"ischemic stroke event","description":"To compare the risk of ischemic stroke among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.","timeFrame":"between 2014 and 2018"},{"measure":"hemorrhagic stroke event","description":"To compare the risk of hemorrhagic stroke among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.","timeFrame":"between 2014 and 2018"},{"measure":"systemic embolism event","description":"To compare the risk of systemic embolism among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.","timeFrame":"2014-2018"},{"measure":"major GI bleeding event","description":"To compare the risk of major GI bleeding among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.","timeFrame":"2014-2018"},{"measure":"major IC bleeding event","description":"To compare the risk of major IC bleeding among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.","timeFrame":"2014-2018"},{"measure":"other major bleeding event","description":"To compare the risk of other major bleeding among patients newly treated with each NOAC separately (apixaban, dabigatran, rivaroxaban) versus VKAs.","timeFrame":"2014-2018"}]},"eligibilityModule":{"eligibilityCriteria":"Inclusion Criteria:\n\n* Age â‰¥18 years on the index date.\n* At least 1 OAC (apixaban, dabigatran, rivaroxaban, VKAs) dispensed during the identification period.\n\nExclusion Criteria:\n\n* Specialty of the physician responsible for the OAC prescription in the index date is one of the following: orthopedics, general surgery, vascular surgery or any other surgical specialty;\n* Duration of OAC therapy during follow-up inferior to the cut-off defined during the feasibility assessment (except if the patient was admitted to in-hospital care during follow-up);\n* The OAC dispensed in the index date was one of the following: dabigatran 75 mg or rivaroxaban 10 mg\n* Hospital claims lacking a diagnosis code indicative of AF during the study period;\n* Hospital claim indicating a diagnosis or procedure code indicative of pregnancy or childbirth during the study period;\n* Hospital claim indicating a diagnosis or procedure code indicative of valvular heart disease, venous thromboembolism, cardiac surgery, pericarditis, hyperthyroidism and thyrotoxicity during the baseline period;\n* Hospital claim indicating a diagnosis or procedure code indicative of hip and knee replacement surgery during the 6 weeks prior to the index date. Patients with past use of OAC will be excluded. Therefore, patients meeting any of the following criteria will be excluded:\n* Had any OAC (apixaban, dabigatran, edoxaban, rivaroxaban, VKAs) dispensed during the 12-month baseline period;\n* Had \\>1 OAC dispensed on the index date.","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"],"studyPopulation":"Adult patients will be selected from the CCF database based on an apixaban, dabigatran, rivaroxaban or VKAs filled prescription between June 16, 2014 and December 31, 2018.","samplingMethod":"NON_PROBABILITY_SAMPLE"},"contactsLocationsModule":{"overallOfficials":[{"name":"Pfizer CT.gov Call Center","affiliation":"Pfizer","role":"STUDY_DIRECTOR"}]},"ipdSharingStatementModule":{"ipdSharing":"NO","description":"Pfizer will provide access to individual de-identified participant data and related study documents (e.g. protocol, Statistical Analysis Plan (SAP), Clinical Study Report (CSR)) upon request from qualified researchers, and subject to certain criteria, conditions, and exceptions. Further details on Pfizer's data sharing criteria and process for requesting access can be found at: https://www.pfizer.com/science/clinical_trials/trial_data_and_results/data_requests."}},"derivedSection":{"miscInfoModule":{"versionHolder":"2024-02-14"},"conditionBrowseModule":{"meshes":[{"id":"D000004617","term":"Embolism"},{"id":"D000006470","term":"Hemorrhage"}],"ancestors":[{"id":"D000014652","term":"Vascular Diseases"},{"id":"D000002318","term":"Cardiovascular Diseases"},{"id":"D000010335","term":"Pathologic Processes"},{"id":"D000016769","term":"Embolism and Thrombosis"}],"browseLeaves":[{"id":"M21996","name":"Stroke","relevance":"LOW"},{"id":"M9246","name":"Hemorrhage","asFound":"Bleeding","relevance":"HIGH"},{"id":"M7474","name":"Embolism","asFound":"Embolism","relevance":"HIGH"},{"id":"M17090","name":"Vascular Diseases","relevance":"LOW"},{"id":"M16376","name":"Thrombosis","relevance":"LOW"},{"id":"M18818","name":"Embolism and Thrombosis","relevance":"LOW"}],"browseBranches":[{"abbrev":"BC10","name":"Nervous System Diseases"},{"abbrev":"BC14","name":"Heart and Blood Diseases"},{"abbrev":"All","name":"All Conditions"},{"abbrev":"BC23","name":"Symptoms and General Pathology"}]},"interventionBrowseModule":{"meshes":[{"id":"D000069552","term":"Rivaroxaban"},{"id":"C000522181","term":"Apixaban"},{"id":"D000069604","term":"Dabigatran"}],"ancestors":[{"id":"D000065427","term":"Factor Xa Inhibitors"},{"id":"D000000991","term":"Antithrombins"},{"id":"D000015842","term":"Serine Proteinase Inhibitors"},{"id":"D000011480","term":"Protease Inhibitors"},{"id":"D000004791","term":"Enzyme Inhibitors"},{"id":"D000045504","term":"Molecular Mechanisms of Pharmacological Action"},{"id":"D000000925","term":"Anticoagulants"}],"browseLeaves":[{"id":"M288142","name":"Apixaban","asFound":"Extraction","relevance":"HIGH"},{"id":"M3934","name":"Anticoagulants","relevance":"LOW"},{"id":"M463","name":"Rivaroxaban","asFound":"Weight loss","relevance":"HIGH"},{"id":"M490","name":"Dabigatran","asFound":"4 hours","relevance":"HIGH"},{"id":"M30203","name":"Factor Xa Inhibitors","relevance":"LOW"},{"id":"M3997","name":"Antithrombins","relevance":"LOW"},{"id":"M3996","name":"Antithrombin III","relevance":"LOW"},{"id":"M14033","name":"Protease Inhibitors","relevance":"LOW"},{"id":"M18081","name":"Serine Proteinase Inhibitors","relevance":"LOW"},{"id":"M19299","name":"HIV Protease Inhibitors","relevance":"LOW"},{"id":"M7641","name":"Enzyme Inhibitors","relevance":"LOW"},{"id":"T18","name":"Serine","relevance":"LOW"}],"browseBranches":[{"abbrev":"AnCoag","name":"Anticoagulants"},{"abbrev":"All","name":"All Drugs and Chemicals"},{"abbrev":"Infe","name":"Anti-Infective Agents"},{"abbrev":"AA","name":"Amino Acids"}]}},"hasResults":false}